about
Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients.Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.Infliximab induces increase in triglyceride levels in psoriatic arthritis patients.Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy.Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases.Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language.Testicular Sertoli cell function in ankylosing spondylitis.Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control
P50
Q30354003-7C6CC58C-5098-41F7-AA51-9985283D9199Q30412466-5318C48A-37E2-49A0-9EFE-197937D7E319Q30420493-E53440FE-C8B0-4006-8048-6993D35B506BQ30432642-D4925A95-4200-4806-BEBF-B45B99DE40FAQ35127601-3D8B8DE2-C487-471B-A6DC-F78F00E7E05BQ36644797-F0CA72CE-2443-4883-B27E-9952272BBE83Q44991197-321E1AF4-FFDE-4420-BECA-B7FCF399FE76Q47823355-7455016A-A313-4E2F-9FBC-5BC030A5EB41Q53119819-470C4060-A975-4FD1-AD5C-EF9E721F30AFQ92578517-71BE6604-9D9D-4C2E-B2B7-941BA6A6B6E4
P50
description
investigador
@es
researcher
@en
name
J C B Moraes
@en
J C B Moraes
@nl
type
label
J C B Moraes
@en
J C B Moraes
@nl
prefLabel
J C B Moraes
@en
J C B Moraes
@nl
P31
P496
0000-0002-5766-6802